These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 24140082)

  • 1. CHEK again: revisiting the development of CHK1 inhibitors for cancer therapy.
    McNeely S; Beckmann R; Bence Lin AK
    Pharmacol Ther; 2014 Apr; 142(1):1-10. PubMed ID: 24140082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chk1 inhibitors for novel cancer treatment.
    Tao ZF; Lin NH
    Anticancer Agents Med Chem; 2006 Jul; 6(4):377-88. PubMed ID: 16842237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel mechanism of checkpoint abrogation conferred by Chk1 downregulation.
    Xiao Z; Xue J; Sowin TJ; Rosenberg SH; Zhang H
    Oncogene; 2005 Feb; 24(8):1403-11. PubMed ID: 15608676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reality CHEK: Understanding the biology and clinical potential of CHK1.
    Neizer-Ashun F; Bhattacharya R
    Cancer Lett; 2021 Jan; 497():202-211. PubMed ID: 32991949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The checkpoint 1 kinase inhibitor LY2603618 induces cell cycle arrest, DNA damage response and autophagy in cancer cells.
    Wang FZ; Fei HR; Cui YJ; Sun YK; Li ZM; Wang XY; Yang XY; Zhang JG; Sun BL
    Apoptosis; 2014 Sep; 19(9):1389-98. PubMed ID: 24928205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ATR/CHK1 inhibitors and cancer therapy.
    Qiu Z; Oleinick NL; Zhang J
    Radiother Oncol; 2018 Mar; 126(3):450-464. PubMed ID: 29054375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Checkpoint kinase inhibitors: a patent review (2009 - 2010).
    Lainchbury M; Collins I
    Expert Opin Ther Pat; 2011 Aug; 21(8):1191-210. PubMed ID: 21599421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor.
    King C; Diaz H; Barnard D; Barda D; Clawson D; Blosser W; Cox K; Guo S; Marshall M
    Invest New Drugs; 2014 Apr; 32(2):213-26. PubMed ID: 24114124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination drug scheduling defines a "window of opportunity" for chemopotentiation of gemcitabine by an orally bioavailable, selective ChK1 inhibitor, GNE-900.
    Blackwood E; Epler J; Yen I; Flagella M; O'Brien T; Evangelista M; Schmidt S; Xiao Y; Choi J; Kowanetz K; Ramiscal J; Wong K; Jakubiak D; Yee S; Cain G; Gazzard L; Williams K; Halladay J; Jackson PK; Malek S
    Mol Cancer Ther; 2013 Oct; 12(10):1968-80. PubMed ID: 23873850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Status of p53 in human cancer cells does not predict efficacy of CHK1 kinase inhibitors combined with chemotherapeutic agents.
    Zenvirt S; Kravchenko-Balasha N; Levitzki A
    Oncogene; 2010 Nov; 29(46):6149-59. PubMed ID: 20729914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cancer therapeutic potential of Chk1 inhibitors: how mechanistic studies impact on clinical trial design.
    Thompson R; Eastman A
    Br J Clin Pharmacol; 2013 Sep; 76(3):358-69. PubMed ID: 23593991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel indication for cancer therapy: Chk1 inhibition sensitizes tumor cells to antimitotics.
    Xiao Z; Xue J; Semizarov D; Sowin TJ; Rosenberg SH; Zhang H
    Int J Cancer; 2005 Jul; 115(4):528-38. PubMed ID: 15688426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a screening assay for surrogate markers of CHK1 inhibitor-induced cell cycle release.
    Fanton CP; Rowe MW; Moler EJ; Ison-Dugenny M; De Long SK; Rendahl K; Shao Y; Slabiak T; Gesner TG; MacKichan ML
    J Biomol Screen; 2006 Oct; 11(7):792-806. PubMed ID: 17035625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chk1 is dispensable for G2 arrest in response to sustained DNA damage when the ATM/p53/p21 pathway is functional.
    Lossaint G; Besnard E; Fisher D; Piette J; Dulić V
    Oncogene; 2011 Oct; 30(41):4261-74. PubMed ID: 21532626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting serine/threonine protein kinase B/Akt and cell-cycle checkpoint kinases for treating cancer.
    Li Q; Zhu GD
    Curr Top Med Chem; 2002 Sep; 2(9):939-71. PubMed ID: 12171565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chk1 and Wee1 control genotoxic-stress induced G2-M arrest in melanoma cells.
    Vera J; Raatz Y; Wolkenhauer O; Kottek T; Bhattacharya A; Simon JC; Kunz M
    Cell Signal; 2015 May; 27(5):951-60. PubMed ID: 25683911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer.
    Smith J; Tho LM; Xu N; Gillespie DA
    Adv Cancer Res; 2010; 108():73-112. PubMed ID: 21034966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LY2606368 Causes Replication Catastrophe and Antitumor Effects through CHK1-Dependent Mechanisms.
    King C; Diaz HB; McNeely S; Barnard D; Dempsey J; Blosser W; Beckmann R; Barda D; Marshall MS
    Mol Cancer Ther; 2015 Sep; 14(9):2004-13. PubMed ID: 26141948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unleashing Chk1 in cancer therapy.
    Carrassa L; Damia G
    Cell Cycle; 2011 Jul; 10(13):2121-8. PubMed ID: 21610326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer.
    Bucher N; Britten CD
    Br J Cancer; 2008 Feb; 98(3):523-8. PubMed ID: 18231106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.